Belumosudil gains FDA nod as chronic GVHD treatment


The FDA has approved Kadmon Holdings' Rezurock, or belumosudil, as a treatment for chronic graft-versus-host disease in pediatric patients age 12 and older who have undergone two prior lines of therapy. The ROCK-2-targeting agent seemed to be well tolerated, and data from a pivotal trial of 65 patients showed 62% didn't require new systemic therapy for one year after treatment with belumosudil.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.